Analysts at RBC Capital Markets and CIBC Capital Markets raised their price targets on DRI Healthcare Trust (DHT-UN.TO) to CA$22 from CA$21, and to CA$21.50 from CA$21, respectively.

RBC analyst Douglas Miehm maintained an outperform rating on shares of the pharmaceutical royalty company while CIBC analyst Erin Kyle maintained an outperformer rating on DRI.

"We see upside to our return profile and NAV estimate depending on the pace of commercialization, which may exceed consensus estimates, and on the timing of cumulative sales milestone payments," Kyle said in a note to clients.

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)